

1 **Chronic respiratory symptoms and chronic obstructive pulmonary disease following**  
2 **completion of pulmonary tuberculosis treatment in Uganda**

3 Martha Namusobya<sup>1</sup>, Felix Bongomin<sup>2,3</sup>, Mukisa John<sup>4</sup>, Ivan Kimuli<sup>5</sup>, Ahmed Ddungu<sup>6</sup>, Charles  
4 Batte<sup>5</sup>, Bruce J. Kirenga<sup>5</sup>

5 Author affiliations:

- 6 1. Department of Clinical Epidemiology and Biostatistics, School of Medicine, College of  
7 Health Sciences, Makerere University, Kampala, Uganda
- 8 2. Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu  
9 University, Gulu, Uganda
- 10 3. Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health,  
11 University of Manchester, M13 9PL, Oxford Road, Manchester, United Kingdom
- 12 4. Department of Immunology and Molecular Biology, School of Biomedical Sciences,  
13 College of Health Sciences, Makerere University, Kampala, Uganda.
- 14 5. Makerere Lung Institute, School of Medicine, College of Health Sciences, Makerere  
15 University, Kampala, Uganda
- 16 6. Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala,  
17 Uganda

18  
19 Correspondence to Dr. Martha Namusobya, Department of Clinical Epidemiology and  
20 Biostatistics, School of Medicine, College of Health Sciences, Makerere University, Kampala,  
21 Uganda. Email: [martharynam@gmail.com](mailto:martharynam@gmail.com)

22

## 23 **Abstract**

### 24 **Background**

25 Prior pulmonary tuberculosis (PTB) is associated with chronic lung impairment, including  
26 chronic obstructive pulmonary disease (COPD). We determined the prevalence and  
27 associations of chronic respiratory symptoms and COPD following completion of PTB treatment  
28 in Uganda.

### 29 **Methods**

30 Between August 2022 and December 2022, we consecutively enrolled post-PTB patients who  
31 had successfully completed PTB treatment between January 2016 and January 2020 at Mulago  
32 National Referral Hospital, Kampala, Uganda. Chronic respiratory symptoms were defined as  
33 the presence of at least one of the following symptoms lasting for at least three months within a  
34 year: cough or sputum production, shortness of breath, chest pain, or wheezing, along with an  
35  $FEV_1/FVC < 0.70$  on spirometry for the definition of COPD.

### 36 **Results**

37 We enrolled 326 participants (median age 36 years; IQR: 30 — 43), 182 (55.8%) were male,  
38 and 123 (37.7%) were living with HIV. Fifty-one (15.6%) participants had chronic respiratory  
39 symptoms, 5 (9.8%) having COPD; 4 GOLD I and 1 GOLD II. Chronic respiratory symptoms  
40 were 89% lower among participants whose PTB treatment outcome was “completed” (adjusted  
41 Odds Ratio (aOR): 0.11, 95% confidence interval (CI): 0.01 – 0.87,  $p < 0.01$ ) and they were 74%  
42 lower among those with alcohol use disorders (aOR: 0.26, 95% CI: 0.12 – 0.57,  $p < 0.001$ ). Non-  
43 HIV immunosuppressive conditions such as diabetes mellitus and chronic steroid use, were  
44 significantly associated with both chronic respiratory symptoms (aOR: 7.72, 95% CI 3.13 –  
45 19.04,  $p < 0.001$ ) and COPD (aOR: 8.42, 95% CI: 1.32 — 53.47,  $p = 0.024$ ).

46 **Conclusion**

47 Chronic pulmonary symptoms, including COPD, are important and yet under recognized  
48 complications of PTB treatment in Uganda. Therefore, screening and management in key sub-  
49 groups, such as those with immunosuppressive condition, will improve morbidity and quality of  
50 life in this population.

51

52 **Keywords**

53 Pulmonary tuberculosis, Chronic Respiratory Symptoms, Chronic Obstructive Pulmonary  
54 Disease, Spirometry, Uganda.

55

56

57

58

59

60

61

62

63

64

65

66

67

## 68 **Introduction**

69 Pulmonary tuberculosis (PTB) is associated with parenchymal destruction leading to alteration  
70 in lung architecture and chronic lung impairment, including chronic obstructive pulmonary  
71 disease (COPD). Many patients remain symptomatic even after 'successful' PTB treatment (1).  
72 Studies done in Brazil and Malawi showed that prevalence of chronic respiratory symptoms  
73 after PTB cure were 45% (2) and 30.7% (3), respectively. The PLATINO study showed that the  
74 overall prevalence of airflow obstruction is over 2-folds higher among subjects with a history of  
75 tuberculosis(TB), compared to those without TB history (4). In this study, a history of prior TB  
76 was associated with a more severe form of COPD (4).

77 COPD is one of the common complications of PTB (1,6,8). A cross-sectional study done among  
78 cured Ugandan drug-resistant (DR) TB patients found a 23% prevalence of COPD(5). This  
79 study didn't include drug-sensitive (DS) TB patients who comprise the majority of TB patients.  
80 Another study in Ethiopia showed the prevalence of COPD among successfully treated PTB  
81 patients (both DS and DR) to be 41.4% (6). The symptoms of COPD (chronic cough, dyspnea,  
82 frequent respiratory infections, fatigue, and wheezing) are similar to PTB symptoms and may  
83 plague TB patients long after cure. This may be misdiagnosed as a TB recurrence, and  
84 managed inappropriately. This may in turn negatively impact patients' quality of life, leading to  
85 increased morbidity, hospital visits, and mortality (7).

86 COPD is the third leading cause of death worldwide (11), causing 3.23 million deaths in 2019  
87 (13). Over 80% of these deaths occurred in low- and middle-income countries (LMICs) (8).  
88 COPD causes persistent and progressive respiratory symptoms, including difficulty in breathing,  
89 cough, and/or phlegm production (8). A study conducted in Malawi showed that at PTB  
90 completion, 60.7% of participants reported respiratory symptoms, and 34.2% had abnormal  
91 spirometry(3). With such staggering statistics, and paucity of data in our own setting, Uganda; it  
92 will be key to not only quantify the burden of post-TB persistent respiratory symptoms and

93 COPD, but also tease out their associations. COPD is manageable, and therefore early  
94 diagnosis in this special population will be key in reducing morbidity, mortality, and informing  
95 management to improve long term outcomes (9, 10).

96 The TB burden in Uganda remains high with a prevalence of 197 per 100,000 population (11),  
97 thus predisposing many patients to the risk of developing chronic lung disease. TB sequelae  
98 include obstructive and restrictive lung diseases, bronchiectasis, pleural disease among others  
99 (5, 12). Therefore, we hypothesized that COPD is highly prevalent among Ugandan adults who  
100 have chronic pulmonary symptoms after PTB treatment. The aim of this study was threefold: to  
101 determine the prevalence of chronic respiratory symptoms after PTB treatment, assess the  
102 prevalence of COPD among participants with these symptoms following successful PTB  
103 treatment, and identify factors associated with chronic respiratory symptoms and COPD in this  
104 population.

105

## 106 **METHODS**

### 107 **Study design**

108 We conducted a cross-sectional study at the National TB Control Center at Mulago National  
109 Referral Hospital (MNRH), Kampala, Uganda between 1<sup>st</sup> August 2022 and 30<sup>th</sup> November  
110 2022.

### 111 **Study Setting**

112 The TB Unit at MNRH serves as the national TB treatment center in Uganda. The unit uses a  
113 mixed model of care, whereby, 1) very sick patients are hospitalized at the start of their TB  
114 treatment until clinically stable, and 2) outpatient care where patients continue treatment from

115 the community under supervision. The unit manages about 1,500 TB patients annually, making  
116 it the largest treatment center in the country.

### 117 **Study population**

118 We enrolled post-PTB patients, both drug-sensitive (DS) and drug resistant (DR), 18 years and  
119 older, who cured or completed treatment between January 2016 and January 2020, and whose  
120 PTB treatment enrollment dates fell in the 2 randomly selected quarters of each cohort year.  
121 Pregnant women, critically ill people, those previously treated for only extra-pulmonary TB,  
122 those with active TB (relapses), and those with history of heart disease were excluded.

### 123 **Sample size estimation**

124 Using previous data of a 30.7% prevalence of persistent pulmonary symptoms in the post-PTB  
125 population (3), at 95% confidence interval (CI), power of 80% and type I error of 5%, a sample  
126 size of 327 participants was estimated.

### 127 **Study procedure**

128 For all eligible participants, a trained medical officer collected data on clinical and demographic  
129 characteristics such as age, sex, HIV status and other key co-morbidities e.g., asthma, clinical  
130 symptoms, alcohol and tobacco use, type of fuel used for cooking, the type of infrastructure in  
131 which cooking happens, occupation, income, and education status using a standardized  
132 structured questionnaire. Participants were consecutively recruited until required sample size  
133 was reached.

### 134 **Spirometry**

135 Participants with chronic respiratory symptoms as ascertained from the questionnaire had  
136 spirometry done to assess for COPD. Spirometry was performed by a trained and experienced

137 spirometry technician and read and interpreted by a pulmonologist at the Makerere University  
138 Lung Institute (MLI). MLI is a center of excellence in innovative lung health research that  
139 integrates disease prevention, clinical care and training.

140 COPD can be estimated with a high diagnostic accuracy using spirometry (13, 14). The  
141 sensitivity for diagnosing airway obstruction in COPD using spirometry is 92% and specificity is  
142 84% (15). The positive predictive value (PPV) is 63%; negative predictive value (NPV) is 97%  
143 (15). A spirometry value of  $FEV_1/FVC < 0.70$  confirmed the presence of persistent airflow  
144 limitation (COPD) (16). The severity of COPD was classified using the Global Initiative for  
145 Chronic Obstructive Lung Disease (GOLD) classification (17).

#### 146 **Data analysis**

147 Participant characteristics that were in form of continuous data were described using medians  
148 and interquartile ranges. Categorical data was presented in frequencies, proportions and  
149 percentages. Comparison between the different categories (e.g. chronic respiratory symptoms  
150 vs no chronic respiratory symptoms and COPD vs no COPD) were made using chi square test  
151 while continuous variable comparisons were done using the Wilcoxon Rank Sum test. Pie  
152 charts and box plots were drawn for data visualization.

153 The prevalence of chronic respiratory symptoms after successful PTB treatment was presented  
154 as proportions/percentages of individuals with any of the symptoms as per the operational  
155 definition. Subgroup analysis was performed considering gender as a possible cause of  
156 difference in prevalence of chronic respiratory symptoms.

157 The prevalence of COPD among participants with chronic respiratory symptoms after successful  
158 PTB treatment was determined by spirometry evaluation. This was categorized as a  
159 dichotomous variable and data was presented as percentages and pie charts. Subgroup

160 analysis was performed considering gender as a possible cause of difference in prevalence of  
161 COPD.

162 To determine factors associated with chronic respiratory symptoms after successful PTB  
163 treatment, the presence of chronic respiratory symptoms was dichotomized into a 1 “yes” 0 “No”  
164 variable. We tested for assumptions for collinearity and outliers before running a logistic  
165 regression model. A bivariate analysis was carried out between the study independent variables  
166 and the presence of chronic respiratory symptoms. Factors with biological plausibility from  
167 literature like age and sex and those with  $P < 0.25$  will be considered for further multivariable  
168 regression analysis. Interaction will be assessed by forming two-way interaction terms and using  
169 the likelihood ratio test to assess significance of the interaction terms. Confounding will be  
170 assessed by considering a change of 10% percent or more in the odds ratios as confounding,  
171 when a model with the variable and one without it are evaluated. The goodness of fit of the final  
172 model will be assessed using the Hosmer-Lemeshow goodness of fit statistics. The odds ratios  
173 and their 95 % confidence intervals will be presented. A  $p < .05$  will be considered statistically  
174 significant. STATA version 14.0 was used for data analysis.

175 To determine factors associated COPD after successful PTB treatment, the presence of COPD  
176 was dichotomized into a 1 “yes” 0 “No” variable and the process of logistic regression above  
177 was repeated but this time with COPD as the outcome variable.

## 178 **Ethics**

179 The Makerere University School of Biomedical Science Research and Ethics Committee (SBS-  
180 2022-131) and the Uganda National Council for Science and Technology (HS2232ES) approved  
181 the study protocol. All study participants provided informed written consent. The authors confirm  
182 that the ethical policies of the journal, as noted on the journal's author guidelines page, have  
183 been adhered to.



## 184 Results

### 185 Baseline characteristics of the participants

186 Of the 326 participants enrolled, 182 (55.8 %) were male with a median age for all participants  
187 of 36 (IQR: 30 — 43) years. One hundred and twenty-three (37.7%) participants were living with  
188 HIV. Majority of the participants, 206 (63.2%), had received Category 1 PTB treatment. A  
189 significant number of participants, 145 (44.5%), had history of alcohol use and 66 (20.2%) had a  
190 history of smoking tobacco. Twenty-six (8%) of participants had history of other  
191 immunosuppressive conditions other than HIV (particularly diabetes and chronic steroid use).  
192 Thirteen (4%) of participants reported history of childhood measles. There were 6 (1.8%)  
193 participants with history of asthma. Four (1.2%) participants had history of severe childhood  
194 respiratory infections e.g., pneumonia. Only 1 (0.3%) participant had history of COPD, lung  
195 cancer and sarcoidosis each. Majority of participants, 274 (84%), used charcoal as their main  
196 source of cooking fuel, whilst majority (46.3%) cooked in kitchens attached to the main house.  
197 (Table 1).

198

199 **Table 1. Baseline characteristics**

Characteristic	Frequency	Percentage %	Median and IQR
<b>Sex</b>			
male	182	55.8	
female	144	44.2	
<b>Age</b>			
Median, IQR			36 (30-43)
<40	215	65.9	
40-49	78	23.9	
50 and above years	33	10.2	
<b>PTB treatment regimen/ category</b>			
Category 1	206	63.2	

Category 2	1	0.3	
Category 4 (DR TB treatment)	119	36.5	
<b>HIV diagnosis</b>			
Positive	123	37.7	
Negative	200	61.3	
Unknown	3	0.9	
<b>Mycobacteria other than tuberculosis history</b>			
Yes	1	0.3	
No	325	99.7	
<b>Asthma history</b>			
Yes	6	1.8	
No	320	98.2	
<b>COPD history</b>			
Yes	1	0.3	
No	325	99.7	
<b>Sarcoidosis history</b>			
Yes	1	0.3	
No	325	99.7	
<b>Lung cancer history</b>			
Yes	1	0.3	
No	325	99.7	
<b>Chicken pox history</b>			
Yes	7	2.1	
No	319	97.9	
<b>Alcoholism history</b>			
Yes	145	44.5	
No	181	55.5	
<b>Any other immunosuppressive conditions other than HIV (e.g. diabetes mellitus, and chronic steroid use) history</b>			
Yes	26	8	
No	300	92	
<b>Smoking history</b>			
Yes	66	20.2	
No	260	79.8	
<b>Measles history</b>			
Yes	13	4	
No	313	96	
<b>History of severe childhood respiratory infections e.g. pneumonia</b>			
Yes	4	1.2	
No	322	98.8	

201

202 **Prevalence of chronic respiratory symptoms.**

203 Of 326 participants, 51 (15.6%) reported at least one of the chronic respiratory symptoms as per  
204 case definition. Forty-eight (14.7%) reported shortness of breath, 31 (9.5%) reported cough, 30  
205 (9.2%) reported chest pain, while 22 (6.7%) reported wheezing, (**Table 2**).

206 **Table 2. Prevalence of chronic respiratory symptoms**

Characteristic	Total, N(%)	Male N(%)	Female, N(%)	P value
<b>Persistent cough</b>				
Yes	31 (9.5)	13 (7.1)	18 (12.5)	
No	295 (90.5)	169 (92.9)	126 (87.5)	0.102
<b>Shortness of breath</b>				
Yes	48 (14.7)	21 (11.5)	27 (18.8)	
No	278 (85.3)	161 (88.5)	117 (81.3)	0.068
<b>Chest pain</b>				
Yes	30 (9.2)	14 (7.7)	16 (11.1)	
No	296 (90.8)	168 (92.3)	128 (88.9)	0.289
<b>Wheezing</b>				
Yes	22 (6.7)	6 (3.3)	16 (11.1)	
No	304 (93.3)	176 (96.7)	128 (88.9)	0.005
<b>No symptoms</b>	275 (83.4)	162 (87.9)	112 (77.8)	0.015

207

208 At multivariable analysis, factors that were statistically significantly associated with chronic  
209 respiratory symptoms were: participants whose successful PTB treatment outcome was  
210 “completed treatment” (aOR: 0.11, 95%CI: 0.01 — 0.87, p=0.037), having any other  
211 immunosuppressive conditions other than HIV (e.g. diabetes mellitus, and chronic steroid use)  
212 (aOR: 7.72, 95%CI: 3.13 — 19.04, p<0.001), and a history of alcoholism (aOR: 0.26, 95%CI:  
213 0.12 — 0.57, p=0.001), (**Table 3**).

214

215 **Table 3. Multivariate analysis of the independent variables to determine their association**  
216 **with presence of chronic pulmonary symptoms.**

<b>Characteristic</b>	<b>Adjusted odds ratio and 95 % CI</b>	<b>P value</b>
<b>PTB treatment outcome</b>		
Cured	Ref	
Completed	0.11 (0.01-0.87)	0.037
<b>Any other immunosuppressive conditions other than HIV (e.g. Diabetes mellitus)</b>		
No	Ref	
Yes	7.72(3.13-19.04)	<0.001
<b>Alcoholism</b>		
No	Ref	
Yes	0.26 (0.12-0.57)	0.001
<b>Age in completed years</b>		
<40	Ref	
40-49	1.54(0.72-3.33)	0.268
50 and above years	1.90 (0.67-5.37)	0.226

217

218 **Prevalence of COPD**

219 In the 51 (15.6%) participants with chronic respiratory symptoms in whom spirometry was  
220 indicated, 5 (9.8%) had COPD. Of the 5 participants with COPD, 4 (80%) had a classification of  
221 GOLD I while 1 (20%) had a classification of GOLD II. Other ventilatory defects on spirometry  
222 were: asthma (n=10, 19.6%), and restrictive lung disease (n=3, 5.9%), **Table 4.**

223 **Table 4. Prevalence of COPD and other findings on spirometry.**

224 **N=51**

<b>Characteristic</b>	<b>Frequency</b>	<b>Percentage</b>
COPD	5	9.8
Asthma	10	19.6
Restriction	3	5.9
Normal spirometry	33	64.7

225

226

227 At multivariable analysis, COPD was independently associated with having other  
228 immunosuppressive conditions other than HIV (e.g., diabetes mellitus, and chronic steroid use)  
229 (aOR: 8.42, 95%CI: 1.32 — 53.47, p=0.024), (Table 5).

230 **Table 5. Multivariate analysis of the independent variables to determine their association**  
231 **with presence of COPD.**

Characteristic	Adjusted odds ratio and 95 % CI	P value
<b>Other immunosuppressive conditions other than HIV (e.g. diabetes mellitus, chronic steroid use) history</b>		
No	Ref	
Yes	8.42 (1.32-53.47)	0.024
<b>Where do you cook from?</b>		
Kitchen attached to main house	Ref	
Kitchen separate from the main house	0.88 (0.09-9.00)	0.915
Outdoors/other	0.38 (0.04-3.78)	0.409

232

233

## 234 Discussion

235 In this study, we found the prevalence of chronic respiratory symptoms among successfully  
236 treated post-TB patients to be 15.6%. Our findings are close in keeping with literature that has  
237 reported post-TB lung sequelae prevalence to range anywhere from 18 – 87% (18) among  
238 successfully treated PTB patients.

239 The prevalence of COPD among those with chronic respiratory symptoms was about 10%. This  
240 prevalence is lower than the 23% that was found when a cross-sectional study was conducted  
241 among cured Ugandan DR TB patients (5). This may likely be because the study recruited only  
242 DR TB patients who make up the biggest population of PTB treatment failures and retreatments  
243 (19) and who thus have worse lung sequelae and higher COPD prevalence.

244 Chronic respiratory symptoms were independently associated with having other  
245 immunosuppressive conditions other than HIV (e.g., diabetes mellitus, and chronic steroid use).  
246 It's quite unsurprising that immunosuppressive states would cause chronic respiratory  
247 symptoms because PTB is a driver for opportunist fungal pathogens e.g. chronic pulmonary  
248 aspergillosis, which flourish in the immunosuppressed host to cause chronic pulmonary  
249 symptoms (20, 21).

250 COPD was also independently associated with immunosuppressive conditions other than HIV  
251 e.g., diabetes mellitus and chronic steroid use. Diabetes has been shown to have adverse  
252 inflammatory effects on lung anatomy and physiology (22) and whose impact is inadvertently  
253 amplified in conditions of concurrent lung damage like post-TB sequelae. Part of COPD  
254 management is use of systemic or inhaled steroids which improve symptoms (23) and this might  
255 be why we saw an association with chronic steroid use. That possibly to relieve symptoms,  
256 these post-TB patients had steroids prescribed whether by self or health workers, even in the  
257 absence of a definitive COPD diagnosis, to improve their quality of life.

258 Despite a relatively high burden of chronic respiratory symptoms among the study participants,  
259 COPD only contributed to about 10% of the etiology of these symptoms. Therefore, multiple  
260 etiologies may explain chronic respiratory symptoms in the settings of post-PTB treatment. In  
261 this study, we were able to show that asthma and restrictive lung disease contributed to an  
262 additional 25% of participants with chronic respiratory symptoms. We have previously shown  
263 that chronic pulmonary aspergillosis (CPA) occurs in up to 20% of PTB patients with persistent  
264 symptoms (24) , significantly affecting their quality of life during PTB treatment (25) . Therefore,  
265 investigations for both infectious complications and ventilatory defects are indicated in patients  
266 with chronic respiratory symptoms following completion of PTB treatment.

267 This study has some limitations. Firstly, this was a single center study, involving mainly patients  
268 from the central region of Uganda and may not be representative of other populations since  
269 epidemiological patterns may differ across populations. Secondly, we did not perform chest  
270 imaging such as chest x-ray or CT scan, which would be helpful to rule out other complications  
271 of post-PTB such as CPA and other differential diagnosis. In addition, further evaluation  
272 including sputum examination to rule out TB relapse and other intercurrent pulmonary infections  
273 were not done. However, we conducted a rigorous respiratory investigation including  
274 spirometry, which is the gold standard for COPD diagnosis. Future, prospective, multicenter  
275 studies are recommended to substantiate our findings and provide further insides into the  
276 pathogenesis of chronic respiratory

## 277 **Conclusions**

278 In conclusion, we demonstrated that chronic respiratory symptoms and COPD where of concern  
279 in the post-TB patient population, particularly those with history of non-HIV immunosuppressive  
280 conditions such as diabetes mellitus and chronic steroid use. COPD is manageable, and  
281 therefore early diagnosis in such special populations will be key in reducing morbidity, mortality,  
282 and informing management to improve long term outcomes. Additionally, beyond just COPD,  
283 other conditions like fungal pathogens may plague post-TB patients and cause chronic  
284 respiratory symptoms. These too should be screened for and appropriately managed among  
285 this patient population for improved outcomes and quality of life.

## 286 **Acknowledgement**

287 We thank the MNRH TB unit for hosting the study. We're grateful to the study team based there  
288 who were key in participant identification and recruitment. We're grateful to MLI who performed  
289 the study spirometry.

## 290 **Funding**

291 This research was supported by the Makerere University Non-Communicable Diseases  
292 (MAKNCD) Research Training Program that is supported by the Fogarty International Centre of  
293 the National Institutes of Health under Award Number D43TWO11401. The content is solely the  
294 responsibility of the authors and does not necessarily represent the official views of the National  
295 Institutes of Health.

## 296 **Disclosure**

297 There is no conflict of interest to disclose.

298

## 299 **REFERENCES**

- 300 1. Chakaya J, Kirenga B, Getahun H. Long term complications after completion of pulmonary  
301 tuberculosis treatment: A quest for a public health approach. *Journal of Clinical Tuberculosis and Other  
302 Mycobacterial Diseases*. 2016;3:10-2.
- 303 2. Nihues SdSE, Mancuzo EV, Sulmonetti N, Sacchi FPC, de Souza Viana V, Netto EM, et al. Chronic  
304 symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients. *The Brazilian Journal of  
305 Infectious Diseases*. 2015;19(5):492-7.
- 306 3. Meghji J, Lesosky M, Joeke E, Banda P, Rylance J, Gordon S, et al. Patient outcomes associated  
307 with post-tuberculosis lung damage in Malawi: a prospective cohort study. *Thorax*. 2020;75(3):269-78.
- 308 4. Sarkar M, Srinivasa, Madabhavi I, Kumar K. Tuberculosis associated chronic obstructive  
309 pulmonary disease. *The Clinical Respiratory Journal*. 2017;11(3):285-95.
- 310 5. Nuwagira E, Stadelman A, Baluku JB, Rhein J, Byakika-Kibwika P, Mayanja H, et al. Obstructive  
311 lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-  
312 sectional study. *Tropical Medicine and Health*. 2020;48(1):34.
- 313 6. Amsalu Bekele MG, Charles B. Sherman, Neil W. Schluger. Prevalence of chronic obstructive  
314 pulmonary disease (COPD) among patients successfully treated for pulmonary tuberculosis in Ethiopia.  
315 *Ethiopian Medical Journal*. 2020;58(April).
- 316 7. Sandelowsky H, Weinreich UM, Aarli BB, Sundh J, Høines K, Stratelis G, et al. COPD – do the right  
317 thing. *BMC Family Practice*. 2021;22(1).
- 318 8. Organisation WH. Chronic pulmonary Aspergillosis. 2021:5.
- 319 9. Miravittles M, Ribera A. Understanding the impact of symptoms on the burden of COPD.  
320 *Respiratory Research*. 2017;18(1).
- 321 10. Hurst JR, Skolnik N, Hansen GJ, Anzueto A, Donaldson GC, Dransfield MT, et al. Understanding  
322 the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life.  
323 *European Journal of Internal Medicine*. 2020;73:1-6.
- 324 11. Ministry of Health U. The National TB and Leprosy Survey. 2022.



- 325 12. Baig IM, Saeed W, Khalil KF. Post-tuberculous chronic obstructive pulmonary disease. *J Coll*  
326 *Physicians Surg Pak*. 2010;20(8):542-4.
- 327 13. Bosse CG, Criner GJ. Using spirometry in the primary care office. A guide to technique and  
328 interpretation of results. *Postgrad Med*. 1993;93(5):122-4, 9-30, 33-6 passim.
- 329 14. Haroon S, Jordan R, Takwoingi Y, Adab P. Diagnostic accuracy of screening tests for COPD: a  
330 systematic review and meta-analysis. *BMJ Open*. 2015;5(10):e008133.
- 331 15. Schneider A, Gindner L, Tilemann L, Schermer T, Dinant GJ, Meyer FJ, et al. Diagnostic accuracy  
332 of spirometry in primary care. *BMC Pulm Med*. 2009;9:31.
- 333 16. Disease GIFCOL. Global Strategy for the Diagnosis, Management, and Prevention of Chronic  
334 Obstructive Pulmonary Disease. 2021:164.
- 335 17. (GOLD) GIfCOLD. 2023 GOLD Report. 2023.
- 336 18. Allwood BW, van der Zalm MM, Amaral AFS, Byrne A, Datta S, Egere U, et al. Post-tuberculosis  
337 lung health: perspectives from the First International Symposium. *Int J Tuberc Lung Dis*. 2020;24(8):820-  
338 8.
- 339 19. Organization WH. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva,  
340 Switzerland; 2019.
- 341 20. Bongomin F. Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health  
342 concern. *PLoS Pathog*. 2020;16(8):e1008742.
- 343 21. Rozaliyani A, Rosianawati H, Handayani D, Agustin H, Zaini J, Syam R, et al. Chronic Pulmonary  
344 Aspergillosis in Post Tuberculosis Patients in Indonesia and the Role of LDBio Aspergillus ICT as Part of  
345 the Diagnosis Scheme. *J Fungi (Basel)*. 2020;6(4).
- 346 22. Gunasekaran K, Murthi S, Elango K, Rahi MS, Thilagar B, Ramalingam S, et al. The Impact of  
347 Diabetes Mellitus in Patients with Chronic Obstructive Pulmonary Disease (COPD) Hospitalization. *J Clin*  
348 *Med*. 2021;10(2).
- 349 23. Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive  
350 pulmonary disease. *Proc Am Thorac Soc*. 2008;5(4):506-12.
- 351 24. Namusobya M, Bongomin F, Mukisa J, Olwit WK, Batte C, Mukashyaka C, et al. Chronic  
352 pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in  
353 Uganda. *Mycoses*. 2022;65(6):625-34.
- 354 25. Namusobya M, Bongomin F, Mukisa J, Batte C, Olwit WK, Rhein J, et al. The Impact of Chronic  
355 Pulmonary Aspergillosis Co-infection on the Health-Related Quality of Life of Patients with Pulmonary  
356 Tuberculosis in Uganda. *Mycopathologia*. 2023.

357